比伐卢定在急性冠脉综合征患者中经皮冠脉介入围手术期临床应用的研究进展  

Research progress of application of bivalirudin in perioperative period of percutaneous coronary intervention in patients with acute coronary syndrome

作　　者：林开斌 陈衎恺 黄冬[1] 杭靖宇[1] 李京波[1] 魏盟[1] 潘晔生 LIN Kaibin;CHEN Kankai;HUANG Dong;HANG Jingyu;LI Jingbo;WEI Meng;PAN Yesheng(The Sixth People′s Hospital Affiliated to Shanghai Jiaotong University,Shang?hai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院,上海 200233 [2]同济大学附属东方医院,上海 200233

出　　处：《实用医学杂志》2019年第21期3269-3275,共7页The Journal of Practical Medicine

基　　金：上海申康面上项目联合攻关课题(编号：SHDC12015318)

摘　　要：比伐卢定作为新型的抗凝药物,直接作用于凝血酶的活性位点从而发挥抗凝作用。然而,目前对于急性冠脉综合征(acute coronary syndrome,ACS)患者在经皮冠脉介入术(percutaneous coronary intervention,PCI)围手术期的抗凝治疗中,若与传统的药物普通肝素进行比较,比伐卢定是否具有更安全、有效的显著优势目前尚无定论。本文以比伐卢定为主要分析对象,将其药理学特性及近5年国际上的临床研究进展综述如下。As a new anticoagulant drug,bivalirudin directly inhabits the active site of thrombin to exert its anticoagulant effects.However,for the anticoagulant therapy during the perioperative period of percutaneous coro?nary intervention(PCI)among the acute coronary syndrome(ACS)patients,it is inconclusive whether bivalirudin has a safer and more effective effect than heparin,the traditional drug.In this paper,we reviewed the pharmacolog?ical properties of bivalirudin and clinical research progress in the past five years.

关 键 词：比伐卢定 普通肝素 经皮冠脉介入治疗 

分 类 号：R54[医药卫生—心血管疾病]